POTENCIAL ATIVIDADE DOS FÁRMACOS OXICONAZOL E LANSOPRAZOL SOBRE FORMAS TRIPOMASTIGOTAS DE Trypanosoma cruzi Dm28c
Autor(a) principal: | |
---|---|
Data de Publicação: | 2024 |
Tipo de documento: | Dissertação |
Idioma: | por |
Título da fonte: | Repositório Institucional da UFMS |
Texto Completo: | https://repositorio.ufms.br/handle/123456789/9067 |
Resumo: | Chagas disease is caused by the protozoan Trypanosoma cruzi. It is classified as a neglected tropical disease and is endemic in Latin America, where up to 7 million people are believed to be infected. The available treatments for this disease are not very effective in the chronic phase and also have adverse effects. The process of discovering new drugs is long and expensive, so drug repositioning strategies are gaining ground as they can reduce costs and time to market. The aim of this study was to evaluate the activity of two drugs, previously selected in silico, on metacyclic trypomastigotes of T. cruzi Dm28c. Cytotoxicity tests were performed with the drugs oxiconazole (OXI) and lansoprazole (LZP) against Vero cells and metacyclic trypomastigote forms obtained in vitro, under chemically defined conditions, with the aim of determining the concentration capable of inhibiting 50% of parasite viability. Subsequently, tests were performed to evaluate the influence of the drugs on the process of metacyclogenesis in vitro. Using the CC50 (50% cytotoxic concentration) and IC50 (50% inhibitory concentration) data, the SI (selectivity index) was calculated. OXI showed a cytotoxic effect with a CC50 of 45.11 μM, in contrast to LZP which showed no cytotoxicity. OXI had an effect on trypomastigote forms with an IC50 of 279.6 μM and an IS of 0.16, while LZP had an IS of 2.46 and less activity against the parasite. Both drugs had an effect on the differentiation process, where intermediate forms were more abundant than metacyclic trypomastigotes, indicating that the drugs affected the process from the onset of differentiation, preventing or delaying its completion. Thus, both drugs had an effect during metacyclogenesis, but only OXI acted against the metacyclic trypomastigote forms. |
id |
UFMS_254324169ab26a58cac7881bbe2d6f3a |
---|---|
oai_identifier_str |
oai:repositorio.ufms.br:123456789/9067 |
network_acronym_str |
UFMS |
network_name_str |
Repositório Institucional da UFMS |
repository_id_str |
2124 |
spelling |
2024-07-22T12:46:56Z2024-07-22T12:46:56Z2024https://repositorio.ufms.br/handle/123456789/9067Chagas disease is caused by the protozoan Trypanosoma cruzi. It is classified as a neglected tropical disease and is endemic in Latin America, where up to 7 million people are believed to be infected. The available treatments for this disease are not very effective in the chronic phase and also have adverse effects. The process of discovering new drugs is long and expensive, so drug repositioning strategies are gaining ground as they can reduce costs and time to market. The aim of this study was to evaluate the activity of two drugs, previously selected in silico, on metacyclic trypomastigotes of T. cruzi Dm28c. Cytotoxicity tests were performed with the drugs oxiconazole (OXI) and lansoprazole (LZP) against Vero cells and metacyclic trypomastigote forms obtained in vitro, under chemically defined conditions, with the aim of determining the concentration capable of inhibiting 50% of parasite viability. Subsequently, tests were performed to evaluate the influence of the drugs on the process of metacyclogenesis in vitro. Using the CC50 (50% cytotoxic concentration) and IC50 (50% inhibitory concentration) data, the SI (selectivity index) was calculated. OXI showed a cytotoxic effect with a CC50 of 45.11 μM, in contrast to LZP which showed no cytotoxicity. OXI had an effect on trypomastigote forms with an IC50 of 279.6 μM and an IS of 0.16, while LZP had an IS of 2.46 and less activity against the parasite. Both drugs had an effect on the differentiation process, where intermediate forms were more abundant than metacyclic trypomastigotes, indicating that the drugs affected the process from the onset of differentiation, preventing or delaying its completion. Thus, both drugs had an effect during metacyclogenesis, but only OXI acted against the metacyclic trypomastigote forms.A doença de Chagas é causada pelo protozoário Trypanosoma cruzi. Classificada como uma Doença Tropical Negligenciada e endêmica da América Latina, acredita-se que até 7 milhões de pessoas estejam infectadas. Os tratamentos disponíveis para essa doença são pouco eficientes na fase crônica, além de apresentarem efeitos adversos. O processo de descoberta de novos fármacos é longo e de alto custo, sendo assim estratégias de reposicionamento de fármacos vem ganhando destaque, pois possibilita a redução de custos e período até sua disponibilização para uso. O objetivo deste trabalho foi avaliar a atividade de dois fármacos, selecionados previamente in silico, sobre formas tripomastigotas metacíclicas de T. cruzi Dm28c. Foram realizados ensaios de citotoxicidade com os fármacos Oxiconazol (OXI) e Lansoprazol (LZP) frente às células Vero e em formas tripomastigotas metacíclicas, obtidas in vitro, sob condições quimicamente definidas com o objetivo de determinar a concentração capaz de inibir 50% da viabilidade dos parasitos. Posteriormente, foram realizados ensaios para avaliar a influência dos fármacos sobre o processo de metaciclogênese in vitro. Com os dados obtidos de CC50 (concentração citotóxica de 50%) e CI50 (concentração inibitória de 50%) foi calculado o IS (Índice de Seletividade). O OXI apresentou efeito citotóxico com CC50 de 45,11 μM, ao contrário do LZP que não apresentou citotoxicidade. O OXI teve efeito sobre formas tripomastigotas, com CI50 de 279,6 μM de 0,16, já o LZP teve um IS de 2,46 e com menor atividade contra o parasito. Ambos os fármacos foram ativos sobre o processo de diferenciação, onde formas intermediárias estiveram mais presentes que as tripomastigotas metacíclicas, revelando que desde o período de deflagração da diferenciação os fármacos afetaram o processo, impedindo ou retardando a finalização do mesmo. Sendo assim, os dois fármacos apresentaram efeito durante a metaciclogênese, contudo, apenas o OXI apresentou atividade contra as formas tripomastigotas metacíclicas.Fundação Universidade Federal de Mato Grosso do SulUFMSBrasilDoença de ChagasIn silicoKinetoplastidaMetaciclogêneseReposicionamento de fármacosPOTENCIAL ATIVIDADE DOS FÁRMACOS OXICONAZOL E LANSOPRAZOL SOBRE FORMAS TRIPOMASTIGOTAS DE Trypanosoma cruzi Dm28cinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisAlda Maria Teixeira FerreiraDANIEL CAMILO FONSECA CAVALCANTIinfo:eu-repo/semantics/openAccessporreponame:Repositório Institucional da UFMSinstname:Universidade Federal de Mato Grosso do Sul (UFMS)instacron:UFMSORIGINALDissertação_Daniel_Camilo.pdfDissertação_Daniel_Camilo.pdfapplication/pdf1123726https://repositorio.ufms.br/bitstream/123456789/9067/-1/Disserta%c3%a7%c3%a3o_Daniel_Camilo.pdfd2f144b81c25df6f4db9c477da095b86MD5-1123456789/90672024-07-22 08:46:57.686oai:repositorio.ufms.br:123456789/9067Repositório InstitucionalPUBhttps://repositorio.ufms.br/oai/requestri.prograd@ufms.bropendoar:21242024-07-22T12:46:57Repositório Institucional da UFMS - Universidade Federal de Mato Grosso do Sul (UFMS)false |
dc.title.pt_BR.fl_str_mv |
POTENCIAL ATIVIDADE DOS FÁRMACOS OXICONAZOL E LANSOPRAZOL SOBRE FORMAS TRIPOMASTIGOTAS DE Trypanosoma cruzi Dm28c |
title |
POTENCIAL ATIVIDADE DOS FÁRMACOS OXICONAZOL E LANSOPRAZOL SOBRE FORMAS TRIPOMASTIGOTAS DE Trypanosoma cruzi Dm28c |
spellingShingle |
POTENCIAL ATIVIDADE DOS FÁRMACOS OXICONAZOL E LANSOPRAZOL SOBRE FORMAS TRIPOMASTIGOTAS DE Trypanosoma cruzi Dm28c DANIEL CAMILO FONSECA CAVALCANTI Doença de Chagas In silico Kinetoplastida Metaciclogênese Reposicionamento de fármacos |
title_short |
POTENCIAL ATIVIDADE DOS FÁRMACOS OXICONAZOL E LANSOPRAZOL SOBRE FORMAS TRIPOMASTIGOTAS DE Trypanosoma cruzi Dm28c |
title_full |
POTENCIAL ATIVIDADE DOS FÁRMACOS OXICONAZOL E LANSOPRAZOL SOBRE FORMAS TRIPOMASTIGOTAS DE Trypanosoma cruzi Dm28c |
title_fullStr |
POTENCIAL ATIVIDADE DOS FÁRMACOS OXICONAZOL E LANSOPRAZOL SOBRE FORMAS TRIPOMASTIGOTAS DE Trypanosoma cruzi Dm28c |
title_full_unstemmed |
POTENCIAL ATIVIDADE DOS FÁRMACOS OXICONAZOL E LANSOPRAZOL SOBRE FORMAS TRIPOMASTIGOTAS DE Trypanosoma cruzi Dm28c |
title_sort |
POTENCIAL ATIVIDADE DOS FÁRMACOS OXICONAZOL E LANSOPRAZOL SOBRE FORMAS TRIPOMASTIGOTAS DE Trypanosoma cruzi Dm28c |
author |
DANIEL CAMILO FONSECA CAVALCANTI |
author_facet |
DANIEL CAMILO FONSECA CAVALCANTI |
author_role |
author |
dc.contributor.advisor1.fl_str_mv |
Alda Maria Teixeira Ferreira |
dc.contributor.author.fl_str_mv |
DANIEL CAMILO FONSECA CAVALCANTI |
contributor_str_mv |
Alda Maria Teixeira Ferreira |
dc.subject.por.fl_str_mv |
Doença de Chagas In silico Kinetoplastida Metaciclogênese Reposicionamento de fármacos |
topic |
Doença de Chagas In silico Kinetoplastida Metaciclogênese Reposicionamento de fármacos |
description |
Chagas disease is caused by the protozoan Trypanosoma cruzi. It is classified as a neglected tropical disease and is endemic in Latin America, where up to 7 million people are believed to be infected. The available treatments for this disease are not very effective in the chronic phase and also have adverse effects. The process of discovering new drugs is long and expensive, so drug repositioning strategies are gaining ground as they can reduce costs and time to market. The aim of this study was to evaluate the activity of two drugs, previously selected in silico, on metacyclic trypomastigotes of T. cruzi Dm28c. Cytotoxicity tests were performed with the drugs oxiconazole (OXI) and lansoprazole (LZP) against Vero cells and metacyclic trypomastigote forms obtained in vitro, under chemically defined conditions, with the aim of determining the concentration capable of inhibiting 50% of parasite viability. Subsequently, tests were performed to evaluate the influence of the drugs on the process of metacyclogenesis in vitro. Using the CC50 (50% cytotoxic concentration) and IC50 (50% inhibitory concentration) data, the SI (selectivity index) was calculated. OXI showed a cytotoxic effect with a CC50 of 45.11 μM, in contrast to LZP which showed no cytotoxicity. OXI had an effect on trypomastigote forms with an IC50 of 279.6 μM and an IS of 0.16, while LZP had an IS of 2.46 and less activity against the parasite. Both drugs had an effect on the differentiation process, where intermediate forms were more abundant than metacyclic trypomastigotes, indicating that the drugs affected the process from the onset of differentiation, preventing or delaying its completion. Thus, both drugs had an effect during metacyclogenesis, but only OXI acted against the metacyclic trypomastigote forms. |
publishDate |
2024 |
dc.date.accessioned.fl_str_mv |
2024-07-22T12:46:56Z |
dc.date.available.fl_str_mv |
2024-07-22T12:46:56Z |
dc.date.issued.fl_str_mv |
2024 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://repositorio.ufms.br/handle/123456789/9067 |
url |
https://repositorio.ufms.br/handle/123456789/9067 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
Fundação Universidade Federal de Mato Grosso do Sul |
dc.publisher.initials.fl_str_mv |
UFMS |
dc.publisher.country.fl_str_mv |
Brasil |
publisher.none.fl_str_mv |
Fundação Universidade Federal de Mato Grosso do Sul |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFMS instname:Universidade Federal de Mato Grosso do Sul (UFMS) instacron:UFMS |
instname_str |
Universidade Federal de Mato Grosso do Sul (UFMS) |
instacron_str |
UFMS |
institution |
UFMS |
reponame_str |
Repositório Institucional da UFMS |
collection |
Repositório Institucional da UFMS |
bitstream.url.fl_str_mv |
https://repositorio.ufms.br/bitstream/123456789/9067/-1/Disserta%c3%a7%c3%a3o_Daniel_Camilo.pdf |
bitstream.checksum.fl_str_mv |
d2f144b81c25df6f4db9c477da095b86 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFMS - Universidade Federal de Mato Grosso do Sul (UFMS) |
repository.mail.fl_str_mv |
ri.prograd@ufms.br |
_version_ |
1815448050494078976 |